SOUTH SAN FRANCISCO, Calif.
May 29, 2014
/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
James M. Gower
, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Conference in
New York City
Tuesday, June 3rd
2:30 p.m. ET
To access the live audio webcast or the subsequent archived recording, log on to
. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel ( www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP in the second quarter of 2014 and a Phase 2 clinical trial for IgA nephropathy in the second half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an AMPK activator in Phase 1 development; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.
Follow us on Twitter - @RigelPharma
SOURCE Rigel Pharmaceuticals, Inc.